No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Gastroenterol Hepatol
Hauptverfasser: Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Patricia, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk, Witt, David J., Silverberg, Michael J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962408/
https://ncbi.nlm.nih.gov/pubmed/29535057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.03.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge